• Login
    View Item 
    •   JScholarship Home
    • Knowledge for the World
    • JHU Open Access Research
    • View Item
    •   JScholarship Home
    • Knowledge for the World
    • JHU Open Access Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies

    Thumbnail
    View/Open
    data/Gaillard%202019%20Gyn%20Onc%20ESR1%20mutations.pdf (1.164Mb)
    Author
    Stéphanie L. Gaillard
    Kaitlyn J. Andreano
    Laurie M. Gay
    Meghan Steiner
    Matthew S. Jorgensen
    Brittany Anne Davidson
    Laura J. Havrilesky
    Angeles Alvarez Secord
    Fidel A. Valea
    Gerardo Colon-Otero
    Deborah A. Zajchowski
    Ching-Yi Chang
    Donald P. McDonnell
    Andrew Berchuck
    Julia A. Elvin
    Metadata
    Show full item record
    Abstract
    OBJECTIVE: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. METHODS: DNA from FFPE tumor tissue obtained during routine clinical care for 9645 gynecologic malignancies (ovary, fallopian tube, uterus, cervix, vagina, vulvar, and placenta) was analyzed for all classes of genomic alterations (base substitutions (muts), insertions, deletions, rearrangements, and amplifications) in ESR1 by hybrid capture next generation sequencing. A subset of alterations was characterized in laboratory-based transcription assays for response to endocrine therapies. RESULTS: A total of 295 ESR1 genomic alterations were identified in 285 (3.0%) cases. mutESR1 were present in 86 (0.9%) cases and were more common in uterine compared to other cancers (2.0% vs <1%, respectively p < 0.001). mutESR1 were enriched in carcinomas with endometrioid versus serous histology (4.4% vs 0.2% respectively, p < 0.0001 in uterine and 3.5% vs 0.3% respectively, p = 0.0004 in ovarian carcinomas). In three of four patients with serial sampling, mutESR1 emerged under the selective pressure of AI therapy. Despite decreased potency of estrogen receptor (ER) antagonists in transcriptional assays, clinical benefit was observed following treatment with selective ER-targeted therapy, in one case lasting >48 months. CONCLUSIONS: While the prevalence of ESR1 mutations in gynecologic malignancies is low, there are significant clinical implications useful in guiding therapeutic approaches for these cancers.
    URI
    http://jhir.library.jhu.edu/handle/1774.2/61858
    Collections
    • JHU Open Access Research

    DSpace software copyright © 2002-2016  DuraSpace
    Policies | Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of JScholarshipCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Policies | Contact Us | Send Feedback
    Theme by 
    Atmire NV